RU-486 Under Attack: Abortion Groups Sue States To Restrict Off-Label Use
Eight years after FDA approved RU-486, two states have engaged in a legal battle to restrict patient access by attempting to prevent physicians from prescribing the abortion pill for off-label uses
You may also be interested in...
Sixteen US states have issued executive orders or other mandatory directives to preserve hydroxychloroquine and chloroquine for non-COVID-19 patients, while 26 states have issued similar voluntary guidance. The federal government is reserving some of the strategic national stockpile supply of the drugs for non-COVID-19, as private players in the supply chain also join in the efforts to balance on-label use with COVID-related demand.
Senators ask the agency to address the “regulatory loophole” permitting telehealth companies to promote prescription drugs without disclosing side effects and question if FDA has enforcement authority over third-party social media influencer promotions.
Draft guidance describes evolution of DMCs and their responsibilities for monitoring trial conduct, internal analyses and external data.